Imatinib Zentiva (Imatinib)

Imatinib works by binding to the ATP‑binding site of specific tyrosine kinases such as BCR‑ABL, KIT and PDGFRA. This blocks the enzymes’ activity, preventing downstream phosphorylation events that are necessary for cancer cell proliferation and survival, ultimately leading to apoptosis of the abnormal cells.

The prescribed dose of Imatinib Zentiva is set by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and individual response to therapy. Dosing regimens may be adjusted over time, and patients should follow the exact instructions provided by their healthcare professional.

Safety data for Imatinib during pregnancy and lactation are limited. Because the drug can cross the placenta and is excreted in breast milk, it is generally advised to avoid use unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To order Imatinib Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib is the first‑generation BCR‑ABL tyrosine kinase inhibitor and is often compared with second‑generation agents such as dasatinib and nilotinib. While newer TKIs may offer faster molecular responses, Imatinib has a well‑established safety profile, extensive long‑term data, and is frequently used as first‑line therapy, especially when cost considerations are important.

Imatinib Zentiva should be stored at temperatures below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and avoid storing in areas of high humidity or heat. Do not freeze the product.

Imatinib Zentiva is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, with or without food, as directed by their prescriber. Consistency in taking the medication at the same time each day helps maintain stable blood levels.

Serious adverse events include severe neutropenia, hepatotoxicity, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Cardiac dysfunction and pulmonary hypertension have also been reported. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and any new cardiac or respiratory symptoms.

Imatinib Zentiva should not be used by individuals with known hypersensitivity to imatinib or any of its excipients. Caution is advised in patients with severe hepatic impairment, uncontrolled heart failure, or significant electrolyte disturbances. The drug is also contraindicated in patients for whom a safer alternative is clinically appropriate.